Healthcare / Medical Instruments & SuppliesKOSDAQ
$19190.00
-280.00 (-1.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $16.5B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$215.6B
P/E
19.1x
↓EV/EBITDA
9.2x
↓ROE
8.2%
↑Gross Margin
35.4%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.2%
FCF CAGR
—
FCF margin
15.5%
FCF / Net income
1.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $118.44B · net income $12.94B · FCF $18.41B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $118.44B | $118.44B | $115.84B | $119.30B | $117.82B |
| Net Income | $12.94B | $12.94B | $184.3M | $3.16B | $18.64B |
| EBITDA | $27.95B | $27.95B | $15.22B | $15.47B | $32.11B |
| EPS | 1007.00 | 1007.00 | 15.00 | 253.00 | 1469.00 |
| Gross Margin | 35.4% | 35.4% | 30.7% | 30.7% | 45.5% |
| Operating Margin | 16.4% | 16.4% | 5.0% | 4.4% | 20.5% |
| Net Margin | 10.9% | 10.9% | 0.2% | 2.6% | 15.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.33 | 0.26 |
| Current Ratio | 2.31 | 2.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $18.41B | $18.41B | $16.47B | $218.1M | $-5.26B |
| Returns | |||||
| ROE | 8.2% | 8.2% | 0.1% | 1.8% | 10.4% |
| Valuation | |||||
| P/E | 19.06 | 19.06 | 1660.00 | 116.40 | 19.20 |
| EV/EBITDA | 9.20 | 9.20 | 21.03 | 27.13 | 12.51 |
| P/B | 1.57 | 1.57 | 1.80 | 2.08 | 2.00 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | -2.9% | 1.3% | — |
| EPS Growth | 6613.3% | 6613.3% | -94.1% | -82.8% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
19.1%
EPS terminal req.
$1702.79
Spread vs growth
6594.2%
5Y implied EPS CAGR
15.4%
EPS terminal req.
$2060.38
Spread vs growth
6597.9%
10Y implied EPS CAGR
12.7%
EPS terminal req.
$3318.26
Spread vs growth
6600.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.7%
Start / end P/E
1148.7x → 19.1x
EPS bridge
15.00 → 1007.00
Residual
-6503.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.